Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Journal: Nature communications
Published: May 10, 2024
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Journal: medRxiv : the preprint server for health sciences
Published: December 18, 2023
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Journal: Nature communications
Published: January 05, 2023
Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer.
Journal: Cancer
Published: November 12, 2020
Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer.
Journal: Breast cancer research and treatment
Published: June 08, 2016
Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor.
Journal: Clinical breast cancer
Published: November 24, 2015
TISSUE REGENERATION. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration.
Journal: Science (New York, N.Y.)
Published: June 13, 2015
Showing 1-10 of 10
Last Updated: 09/26/2026